Advances in Circulating Tumor Cells (ACTC)

It is our great pleasure to invite basic and clinical researchers interested in the field of Circulating Tumour Cells to the 1st “ACTC: Advances in Circulating Tumour Cells” meeting that will be held in Athens, Greece, on September 26th - 29th, 2012. After successfully organizing the 7th International Symposium on Minimal Residual Cancer in Athens, Greece, ( and the very positive feedback that we got from most participants we decided to organize this new meeting in Greece.
Circulating Tumour Cells (CTCs) present in the peripheral blood and Disseminating tumour cells (DTCs) present in bone marrow can now be detected and characterized at the single cell level. These cells are highly relevant to the study of the biology of early metastatic spread and provide a diagnostic source in patients with overt metastases. Research on CTCs present nowadays a challenge, as these cells are well defined targets for understanding tumour biology and improving cancer treatment.
The ACTC meeting is focused on CTC utilisation in clinical practice by bringing together researchers and clinicians to discuss practical implementation of CTCs and translate much of the excellent basic research in this field into clinical practice. The most prominent and established researchers in the field will present state of the art research on the biology of metastasis and on the technical advancements in the isolation, detection and molecular characterization of CTCs. Latest findings on the clinical applications of CTCs in real time monitoring of systemic anticancer therapies will be discussed. A particular emphasis will be given on the relationship of CTCs to cancer stem cells and the relevance of recent findings for the development and use of new targeted therapies in oncology. Our main objectives, is to organize a meeting where latest research will be presented by prominent and established researchers in the field and which will bring together and stimulate intense discussions between both basic and clinical researchers in the field.
We are looking forward to welcoming you and your colleagues in Athens in September 2012,
Evi S. Lianidou, University of Athens, Greece
Dimitris Mavroudis, University of Crete, Greece
Klaus Pantel, University of Hamburg, Germany

+ show speakers and program
1. Julio Aguirre-Ghiso, Associate Professor, Mount Sinai School of Medicine , New York, USA: “Clinical evidence for cancer dormancy and Circulating Tumor Cells”
2. Catherine Alix-Panabières PhD, Laboratoire Cellules Circulantes Rares Humaines - LCCRH, Institut de Recherche en Biothérapie - IRB , Hôpital Saint-Eloi - CHRU Montpellier, France: “EPISPOT assay”.
3. Marija Balic PhD, Department of Internal Medicine, Medical University of Graz, Austria: “Multimarker assessment of putative disseminating breast cancer stem cells.”
4. George A. Calin, M.D., Ph.D., Associate Professor, Department of Experimental Therapeutics , The University of Texas, M. D. Anderson Cancer Center, Houston, Texas, USA: Novel Discoveries and Future Challenges: The role of microRNAs in metastasis
5. Richard J. Cote, M.D., FRCPath, Professor and Chair, Department of Pathology, University of Miami Miller School of Medicine: “Portable filter-based microdevice for detection and characterization of circulating tumor cells”.
6. Michael F. Clarke, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, CA: “Tumorigenic Breast-cancer cells and metastasis.”
7. Massimo Cristofanilli, MD, FACP, Chairman of the Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA: “Circulating tumor cells in breast cancer: A tool whose time has come of age”
8. Caroline Dive, PhD, Paterson Institute for Cancer Research, Manchester, UK: “Clinical Significance and Molecular Characteristics of Circulating Tumor Cells and Circulating Tumor Microemboli in Patients with Small-Cell Lung Cancer”
9. Tanja Fehm, Professor, Department of Gynecology, University of Tuebingen, Germany: “Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast.”
10. Dave Hoon, M.Sc., Ph.D, Director, Department of Molecular Oncology, John Wayne cancer Institute, Santa Monica, CA: “CTCs and other prognostic molecular biomarkers for cutaneous malignant melanoma”
11. Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium: “HER2-Positive Circulating Tumor Cells in Breast Cancer”.
12. Wolfgang Janni, Professor, Universitätsklinikum Frauenklinik, Düsseldorf , Nordrhein-Westfalen, Germany. “Success study on CTC in the adjuvant setting”
13. Sabine Kasimir-Bauer, PhD, Professor, Head of Laboratory, Dep. of Gynecology and Obstetrics, University Hospital of Essen, Germany: The prognostic value of circulating tumor cells in gynecological cancers by using molecular methods.
14. Yibin Kang, PhD, Associate Professor, Department of Molecular Biology, Washington Road, LTL 255, Princeton University, Princeton, New Jersey, USA: “Unravelling the complexity of metastasis — molecular understanding and targeted therapies”.
15. Christoph A. Klein, MD, Professor, Head of the Chair, Division of Oncogenomics, Department of Pathology, University of Regensburg, Regensburg, Germany: “Genetic disparity between primary tumours, disseminated tumour cells, and manifest metastasis”.
16. Hasan Korkaya, D.V.M., Ph.D., Research Assistant Professor, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA : “IL-6 regulated breast CSCs play role in trastuzumab resistance and metastasis”
17. Peter Kuhn, Associate Professor, Scripps Physics Oncology Center, The Scripps Research Institute, San Diego, CA, USA: “Fluid Biopsy of Solid Tumors, a real-time window into cancer evolution in individual patients.”
18. Evi Lianidou, PhD, University of Athens, Greece. “Molecular characterization of CTCs”.
19. Mavroudis D, Professor, MD, PhD, University of Crete, Greece: “Therapy-resistant CTCs: prognostic and therapeutic implications”
20. Michael Mindrinos, PhD, Associate Director, Stanford Genome Technology Center, Dept. of Biochemistry, Stanford University, CA, USA
21. Masaki Mori, Professor, MD, PhD Department of Surgical Oncology, Osaka University, Graduate School of Medicine, Osaka, Japan: “Clinical significance of circulating tumor cells in patients with colorectal cancer.”
22. Bjorn Naume, Professor, Oslo University Hospital, Division of Surgery and Cancer Medicine, Department of Oncology, Oslo, Norway: “Disseminated Tumor Cells in Breast Cancer Patients”
23. Klaus Pantel, Professor, Director, Institute of Tumour Biology, Centre of Experimental Medicine, University Medical Centre Hamburg Eppendorf, Hamburg, Germany: “Detection, Characterization and Clinical relevance of CTCs”
24. Jean-Yves Pierga, MD, PhD, Professor of Medical Oncology, at the Institute Curie and University Paris Descartes, Paris, France: “Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy.”
25. Leon Terstappen, Professor, Faculty of Science and Technology, MIRA Research Institute, Department of Medical Cell BioPhysics, University of Twente, Enschede, the Netherlands: “The frequency of Circulating Tumor Cells”
26. Jean Paul Thiery, Professor, Deputy Director, Institute of Molecular and Cell Biology, BIOPOLIS, Singapore: “Epithelial-mesenchymal transitions in cancer onset and progression”
27. Andreas Trumpp, Professor and Head of the Department for Cell Biology, German Cancer Research Center (DKFZ) Heidelberg, Germany: “Dormant blood stem cells and circulating cancer stem cells”.
28. Danny R. Welch, Ph.D., Professor & Chair, Department of Cancer Biology, Associate Director - Basic Sciences, KU Cancer Center, Kansas Bioscience Authority Eminent Scholar Director, Graduate Program in Cancer Biology, Director, NFCR Center for Metastasis Research, Deputy Editor, Cancer Research: “Metastasis suppressor genes at the interface between the environment and tumor cell growth”.
29. Max Wicha, M.D., Professor, Department of Internal Medicine, Director, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA: “Stem cells in normal development and cancer.”

25 Sep - 29 Sep 2012

meeting website